Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration
Luis Arias1,2, Jordi Monés11Institut de la Màcula i de la Retina, Centro Médico Teknon, Barcelona; 2Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, BarcelonaPurpose: To determine the efficacy and safety of treating predominant...
Saved in:
Main Authors: | Luis Arias, Jordi Monés |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2010
|
Subjects: | |
Online Access: | https://doaj.org/article/b7d3fceb56d244fea27dc88ec79a3637 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Learning curve of sutureless transconjunctival 20-gauge vitrectomy
by: Simanjuntak GWS, et al.
Published: (2014) -
Bacterial endophthalmitis following 25-gauge transconjunctival sutureless vitrectomy
by: Drew N Sommerville, et al.
Published: (2008) -
Sympathetic ophthalmia after 23-gauge transconjunctival sutureless vitrectomy
by: Masatoshi Haruta, et al.
Published: (2010) -
Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion
by: Kumagai K, et al.
Published: (2019) -
Outcome of 20-gauge transconjunctival cannulated sutureless vitrectomy using silicone oil or air tamponade
by: Mohamed AA, et al.
Published: (2013)